RD
Insider
Raymond Debbane
DirectorRaymond Debbane (Director) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in LXRX. Across 3 priced purchase filings, the average 21-session return was +11.5% from execution and +12.3% from disclosure (delay-adjusted; derived). The largest single filing was $277K of LXRX (210,545 sh across 2 lots, as filed), executed Feb 17. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+11.5%
avg across 3 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+12.3%
same 3 filings, from disclosure
Filings, ttm
3
3 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$572K
shares × price, as filed
Last traded
Feb 23
Filed Feb 25
Volume by month
Buys $572K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Most traded names
LXRX
LXRX
3 buys · 0 sells
3 filings
Recent filings
LXRXPURCHASE
LEXICON PHARMACEUTICALS, INC.
View filing →
$147K100,000 sh × $1.47
Exec Feb 23
Filed Feb 25 · 7:00 AM ET LXRXPURCHASE LEXICON PHARMACEUTICALS, INC. View filing → $148K
100,000 sh × $1.48
Exec Feb 20
Filed Feb 23 · 7:49 AM ET LXRXPURCHASE LEXICON PHARMACEUTICALS, INC. View filing → $277K
210,545 sh across 2 lots
Exec Feb 17
Filed Feb 18 · 4:30 PM ET